C/EBPα is inactivated in multiple tumor types [12], whereas the naturally occurring dominant negatively acting C/EBPβ (LIP) is upregulated in breast cancer, suggesting that unbalanced expression of C/EBPβ isoforms may contribute to cancer progression [14]. Here, CEBPB is linked to breast carcinoma.